Shiga Toxin Activates Complement and Binds Factor H: Evidence for an Active Role of Complement in Hemolytic Uremic Syndrome1

Infections with enterohemorrhagic Escherichia coli (EHEC) are a major cause of hemolytic uremic syndrome (HUS). Shiga toxins (Stxs), especially Stx2, are believed to represent major virulence factors of EHEC, contributing to HUS pathogenesis. Beside EHEC-associated HUS, there are hereditary atypical forms of HUS, which are mostly caused by mutations of complement regulators. The aim of the present study was to investigate whether or not complement is also involved in the pathogenesis of EHEC-induced typical HUS, by being activated either directly or indirectly by involvement of its inhibitors. Purified Stx2 markedly activated complement via the alternative pathway and was found to bind to factor H (FH), however, only when it was active. No apparent cleavage or destruction of FH was visible, and cofactor activity in fluid phase was unaffected, but clearly delayed for surface-attached FH, where it is essential for host cell protection. Binding studies using FH constructs revealed that Stx2 binds to short consensus repeats (SCRs) 6–8 and SCRs18–20, but not to SCRs16–17, i.e., to regions involved in the surface recognition function of FH. In conclusion, complement, and in particular FH, not only plays an important role in atypical HUS, but most probably also in EHEC-induced HUS.

[1]  H. Cook,et al.  Shiga toxin‐2 results in renal tubular injury but not thrombotic microangiopathy in heterozygous factor H‐deficient mice , 2009, Clinical and experimental immunology.

[2]  H. Jarva,et al.  Complement factor H allotype 402H is associated with increased C3b opsonization and phagocytosis of Streptococcus pyogenes , 2008 .

[3]  G. Remuzzi,et al.  The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome. , 2008, Journal of the American Society of Nephrology : JASN.

[4]  A. Friedrich,et al.  New Immuno-PCR Assay for Detection of Low Concentrations of Shiga Toxin 2 and Its Variants , 2008, Journal of Clinical Microbiology.

[5]  R. Würzner,et al.  Prevention and treatment of enterohemorrhagic Escherichia coli infections in humans , 2008, Expert review of anti-infective therapy.

[6]  M. Dierich,et al.  The Shiga toxin genotype rather than the amount of Shiga toxin or the cytotoxicity of Shiga toxin in vitro correlates with the appearance of the hemolytic uremic syndrome. , 2007, Diagnostic microbiology and infectious disease.

[7]  D. Uhrín,et al.  Structural basis for complement factor H–linked age-related macular degeneration , 2007, The Journal of experimental medicine.

[8]  John D Lambris,et al.  The role of complement in inflammatory diseases from behind the scenes into the spotlight. , 2007, The American journal of pathology.

[9]  A. Blom,et al.  The Factor H Variant Associated with Age-related Macular Degeneration (His-384) and the Non-disease-associated Form Bind Differentially to C-reactive Protein, Fibromodulin, DNA, and Necrotic Cells* , 2007, Journal of Biological Chemistry.

[10]  John D Lambris,et al.  The C-terminus of complement factor H is essential for host cell protection. , 2007, Molecular immunology.

[11]  R. Würzner,et al.  What makes an enterohemorrhagic Escherichia coli? , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  Victoria A. Higman,et al.  His-384 Allotypic Variant of Factor H Associated with Age-related Macular Degeneration Has Different Heparin Binding Properties from the Non-disease-associated Form* , 2006, Journal of Biological Chemistry.

[13]  P. Jennings,et al.  Mechanisms of Neutrophil Transmigration Across Renal Proximal Tubular HK-2 Cells , 2006, Cellular Physiology and Biochemistry.

[14]  C. Sabin,et al.  Human serum amyloid P component protects against Escherichia coli O157:H7 Shiga toxin 2 in vivo: therapeutic implications for hemolytic-uremic syndrome. , 2006, The Journal of infectious diseases.

[15]  H. Karch,et al.  Epidemiology, Clinical Presentation, and Pathophysiology of Atypical and Recurrent Hemolytic Uremic Syndrome , 2006, Seminars in thrombosis and hemostasis.

[16]  H. Karch,et al.  Enterohaemorrhagic Escherichia coli in human medicine. , 2005, International journal of medical microbiology : IJMM.

[17]  R. T. Smith,et al.  A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[18]  F. Proulx,et al.  Mannan‐binding lectin in children with Escherichia coli O157:H7 haemmorrhagic colitis and haemolytic uraemic syndrome , 2003, Clinical and experimental immunology.

[19]  S. Ranganathan,et al.  A common site within factor H SCR 7 responsible for binding heparin, C-reactive protein and streptococcal M protein. , 2000, European Journal of Immunology.

[20]  D. Pérez-Caballero,et al.  Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome. , 2002, American journal of human genetics.

[21]  P. Ray,et al.  Pathogenesis of Shiga toxin-induced hemolytic uremic syndrome , 2001, Pediatric Nephrology.

[22]  V. V. van Hinsbergh,et al.  Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome. , 2000, Blood.

[23]  J. Samuel,et al.  Interaction of Shiga toxins with human brain microvascular endothelial cells: cytokines as sensitizing agents. , 1999, The Journal of infectious diseases.

[24]  L. Monnens,et al.  Monocyte Chemoattractant Protein-1 and Interleukin-8 Levels in Urine and Serum of Patents with Hemolytic Uremic Syndrome , 1998, Pediatric Research.

[25]  T. Horiuchi,et al.  C5a Induces Tissue Factor Activity on Endothelial Cells , 1997, Thrombosis and Haemostasis.

[26]  P. Lachmann,et al.  Molecular basis of the complement C7 M/N polymorphism. A neutral amino acid substitution outside the epitope of the allospecific monoclonal antibody WU 4-15. , 1995, Journal of immunology.

[27]  J. Samuel,et al.  Purified Shiga-like toxins induce expression of proinflammatory cytokines from murine peritoneal macrophages , 1994, Infection and immunity.

[28]  P. Lachmann,et al.  Complement-mediated adipocyte lysis by nephritic factor sera , 1993, The Journal of experimental medicine.

[29]  G. Fick,et al.  Hypocomplementemia and leukocytosis in diarrhea-associated hemolytic uremic syndrome. , 1992, Nephron.

[30]  R. Cotran,et al.  Cytokine-endothelial interactions in inflammation, immunity, and vascular injury. , 1990, Journal of the American Society of Nephrology : JASN.

[31]  T. Barrett,et al.  Evidence for participation of the macrophage in Shiga-like toxin II-induced lethality in mice. , 1990, Microbial pathogenesis.

[32]  P. Lambert,et al.  The complement system in hemolytic-uremic syndrome in childhood. , 1980, Clinical nephrology.